1. The Core Thesis: A $58 Billion Industry Running a $400 Billion Race India’s pharmaceutical sector occupies a paradoxical position […]
Who this is for: Pharma and biotech IP teams, R&D leads, portfolio managers, and institutional investors tracking the $654 billion
Personalized Medicine Patent Strategy: The Complete IP Playbook for Pharma and Biotech Read Post »
A deep-dive reference for pharma IP teams, ANDA filers, litigation counsel, and institutional investors. Updated 2025. What the Orange Book
The pharmaceutical industry loves a good narrative about convergence. Drugs are meeting devices. Biologics are meeting sensors. Software is meeting
Global Key Takeaways The WHO Essential Medicines List covers more than 500 drugs that health systems are expected to keep
Optimization of Pharmaceutical R&D Portfolios: Strategic IP Valuation and Risk Mitigation in Regulated Markets Pharmaceutical R&D requires a capital allocation
Mastering Strategic Decision-Making in the Pharmaceutical R&D Portfolio Read Post »
Executive Summary: The Transatlantic Bifurcation The global life sciences industry stands at a critical juncture, navigating a bipolar regulatory order
Drugs and Devices: Comparison of European and U.S. Approval Processes Read Post »
Executive Summary: The Structural Redesign of an Industry The pharmaceutical sector, historically characterized by its defensive moats of intellectual property
Section 1: The Economic Architecture of Modern Drug Development The numbers that define pharmaceutical R&D productivity are brutal and well-documented.
Outsourcing Drug Development: The Definitive Pharma IP and Operations Playbook Read Post »
Sign in or create a free account to read this DrugPatentWatch article
